11 HRT Myths That Are Still Scaring Women Away From Treatment in 2025
The number of women who've told me they 'tried to tough it out' because they were scared of HRT — and then felt like a different person within weeks of starting it — is genuinely heartbreaking. The fear made sense in 2002. It doesn't hold up in 2025, and nobody should be white-knuckling perimenopause based on a headline that's been walked back by the researchers who wrote it.
Learn more about Rose →Myth: HRT causes breast cancer
The original WHI finding of increased breast cancer risk applied to a specific combined oral HRT formulation — conjugated equine oestrogen plus medroxyprogesterone acetate — taken by women whose average age was 63, well past the menopause window most women are in when they start treatment. The absolute risk increase was small (about 8 extra cases per 10,000 women per year), and subsequent analysis showed no increased risk for oestrogen-only HRT in women without a uterus. Body-identical progesterone, now widely prescribed, carries a significantly lower breast cancer signal than synthetic progestogens in observational data, though long-term RCT data are still maturing.
Myth: HRT causes heart attacks
The WHI data suggested cardiovascular harm, but the average participant was 63 — more than a decade past menopause — and already had age-related arterial changes. The 'timing hypothesis,' now supported by multiple studies including the KEEPS and ELITE trials, shows that starting HRT within ten years of menopause onset or before age 60 is associated with reduced cardiovascular risk, not increased risk. Oestrogen has known cardioprotective effects on the vascular endothelium when introduced early enough that arteries can still respond.
Myth: HRT causes weight gain
Weight gain during perimenopause and menopause is real, but it is driven by declining oestrogen shifting fat distribution toward the abdomen, slowing metabolism, and disrupting sleep — not by HRT itself. Controlled studies consistently show that HRT does not cause net weight gain and may modestly reduce the central fat accumulation associated with oestrogen loss. Women who gain weight after starting HRT are experiencing a process that would have happened regardless; in some cases HRT may be slowing it.
Myth: You should take HRT for the shortest possible time
The 'shortest time, lowest dose' guidance was a cautious response to the 2002 WHI panic and has since been revised by the British Menopause Society, the Menopause Society (formerly NAMS), and the European Menopause and Andropause Society. Current guidance recognises that duration of use should be an individual decision based on symptom burden, quality of life, and personal risk profile — not a blanket five-year ceiling. For many women, the benefits of continued HRT, including bone protection and cardiovascular timing effects, outweigh the risks well beyond that arbitrary threshold.
Myth: HRT is only for hot flushes
Hot flushes are the symptom most associated with HRT in public understanding, but oestrogen and progesterone receptors are distributed throughout the brain, bones, cardiovascular system, urogenital tract, skin, and joints. HRT addresses a physiologically much broader range of symptoms including disrupted sleep, anxiety, joint pain, vaginal atrophy, urinary urgency, cognitive fog, and reduced bone density. Treating HRT as a 'hot flush pill' means many women with debilitating non-vasomotor symptoms are never offered it.
Myth: HRT is addictive and your body will depend on it
HRT replaces hormones that the body previously produced itself; stopping it does not trigger withdrawal in the clinical sense that addictive substances do. When HRT is stopped, oestrogen levels decline and symptoms that were being treated may return — which is the underlying condition reasserting itself, not a dependency syndrome. The experience of feeling worse after stopping is physiologically identical to simply not having started: the menopause was always there, and it resumes.
Myth: Natural menopause is healthier than managed menopause
There is no physiological virtue in enduring severe symptoms without treatment. Untreated oestrogen deficiency is associated with accelerated bone loss, increased cardiovascular risk, urogenital atrophy, and — in growing evidence — higher dementia risk over decades. The framing of HRT as 'unnatural' ignores that the rapid hormonal withdrawal of modern menopause (which now commonly spans 30+ post-reproductive years) is itself an evolutionary novelty that medicine can reasonably address.
Myth: Bioidentical hormones from compounding pharmacies are safer than regulated HRT
Custom-compounded 'bioidentical' hormones are marketed as natural and personalised, but they are not subject to the same manufacturing standards, dosage consistency checks, or safety trials as regulated body-identical HRT. Regulated transdermal oestradiol and micronised progesterone — available on prescription — are themselves bioidentical in molecular structure and have an established evidence base. Compounded preparations carry the risk of inconsistent dosing without offering proven additional benefit.
Myth: HRT raises blood clot risk for everyone
Oral oestrogen does carry a small increased VTE (venous thromboembolism) risk because it passes through the liver and affects clotting factor synthesis. Transdermal oestrogen — patches, gels, and sprays — bypasses the liver entirely and is not associated with elevated clot risk in observational studies, including in women who are overweight or have other mild risk factors. For the majority of women, transdermal delivery is the standard of care precisely because it avoids this issue.
Myth: Women with a family history of breast cancer cannot take HRT
A family history of breast cancer is not an automatic contraindication to HRT, though it warrants a more detailed personal risk conversation. The relevant factors include whether the family history is first-degree, whether genetic testing has been done (BRCA1/2 status), the woman's baseline density and screening history, and the type of HRT under consideration. Many women with a family history are appropriate candidates for HRT, particularly transdermal oestrogen with body-identical progesterone, and blanket refusal by clinicians is not supported by current guidance.
Myth: Antidepressants are a safer alternative to HRT for mood symptoms
SSRIs and SNRIs are sometimes prescribed as a first-line alternative to HRT for perimenopause-related low mood, anxiety, and irritability — but the mood disruption of perimenopause is primarily driven by hormonal fluctuation, not serotonin deficiency. For women whose mood symptoms are rooted in oestrogen instability, HRT treats the actual cause; antidepressants do not and carry their own side effect profile including reduced libido, weight changes, and discontinuation symptoms. Antidepressants remain appropriate for women with clinical depression or genuine contraindications to HRT, but they are not a like-for-like swap.
Want to go deeper?
Rose covers every symptom, supplement, and condition in full detail — evidence-graded and agenda-free.
Rose is a free, evidence-based reference built for women navigating perimenopause and menopause. No ads. No products to sell. No agenda. Just honest answers — because every woman in this season deserves a trusted friend who has done the research.